The estimated Net Worth of Robert Nelsen is at least $21.4 Million dollars as of 22 March 2021. Mr. Nelsen owns over 3,253 units of Denali Therapeutics Inc stock worth over $280,495 and over the last 21 years he sold DNLI stock worth over $20,745,501. In addition, he makes $395,076 as Independent Director at Denali Therapeutics Inc.
Sign up
Mr. Nelsen DNLI stock SEC Form 4 insiders trading
Robert has made over 9 trades of the Denali Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 3,253 units of DNLI stock worth $88,091 on 22 March 2021.
The largest trade he's ever made was buying 1,000,000 units of Denali Therapeutics Inc stock on 16 October 2019 worth over $20,000,000. On average, Robert trades about 38,354 units every 34 days since 2003. As of 22 March 2021 he still owns at least 10,358 units of Denali Therapeutics Inc stock.
You can see the complete history of Mr. Nelsen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Nelsen biography
Robert T. Nelsen M.D. serves as Independent Director of the Company.D. is Independent Director of the company. Mr. Nelsen co-founded ARCH Venture Partners, L.P., a venture capital firm focused on early-stage technology companies, in 1986 and has served as a Managing Director of ARCH Venture Partners or its affiliated entities since 1994. Mr. Nelsen has served on the board of directors of Vir Biotechnology, Inc. since January 2017, Unity Biotechnology, Inc. since November 2011, Karuna Therapeutics, Inc. since August 2018 and Beam Therapeutics since June 2017, each a public biotechnology company, and currently serves on the board of directors of a number of private companies. Mr. Nelsen previously served on the board of directors of a number of public biotechnology companies, including Agios Pharmaceuticals, Inc. from 2007 to June 2017, Fate Therapeutics, Inc. from 2007 to June 2014, Syros Pharmaceuticals, Inc. from 2012 to June 2018, Sage Therapeutics, Inc. from 2013 to March 2016, Juno Therapeutics, Inc. from 2013 to March 2018 (until it was acquired by Celgene Corporation), Bellerophon Therapeutics, Inc. from February 2014 to November 2015, Sienna Biopharmaceuticals, Inc. from October 2015 to September 2018 and Gossamer Bio, Inc. from January 2018 to December 2018 (prior to its initial public offering). He previously served as a trustee of the Fred Hutchinson Cancer Research Institute and the Institute for Systems Biology, and was a member of the board of directors of the National Venture Capital Association. Mr. Nelsen received his M.B.A. from the University of Chicago and his B.S. from the University of Puget Sound with majors in Economics and Biology.
What is the salary of Robert Nelsen?
As the Independent Director of Denali Therapeutics Inc, the total compensation of Robert Nelsen at Denali Therapeutics Inc is $395,076. There are 15 executives at Denali Therapeutics Inc getting paid more, with Ryan Watts having the highest compensation of $4,978,610.
How old is Robert Nelsen?
Robert Nelsen is 56, he's been the Independent Director of Denali Therapeutics Inc since 2015. There are 8 older and 11 younger executives at Denali Therapeutics Inc. The oldest executive at Denali Therapeutics Inc is Vicki Sato, 71, who is the Independent Chairman of the Board.
What's Robert Nelsen's mailing address?
Robert's mailing address filed with the SEC is C/O VIR BIOTECHNOLOGY, INC., 1800 OWENS STREET, SUITE 900, SAN FRANCISCO, CA, 94158.
Insiders trading at Denali Therapeutics Inc
Over the last 7 years, insiders at Denali Therapeutics Inc have traded over $438,930,443 worth of Denali Therapeutics Inc stock and bought 275,000 units worth $4,950,000 . The most active insiders traders include Llc Fmr, Douglas Kakdl, L.P.Crestlin... und Jay T Flatley. On average, Denali Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,606,006. The most recent stock trade was executed by Vicki L Sato on 3 September 2024, trading 3,080 units of DNLI stock currently worth $77,000.
What does Denali Therapeutics Inc do?
denali therapeutics inc. (“denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including alzheimer’s disease, parkinson’s disease, als and others. denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. founding investors include fidelity biosciences, arch venture partners, flagship ventures and the alaska permanent fund (represented by crestline investors).
What does Denali Therapeutics Inc's logo look like?
Complete history of Mr. Nelsen stock trades at Agios Pharmaceuticals Inc, Bellerophon Therapeutics Inc, Fate Therapeutics Inc, Illumina Inc, Sage Therapeutics Inc, Syros Pharmaceuticals, Denali Therapeutics Inc, Unity Biotechnology Inc, Karuna Therapeutics Inc, Vir Biotechnology Inc und Beam Therapeutics
Denali Therapeutics Inc executives and stock owners
Denali Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Ryan Watts,
President, Chief Executive Officer, Co-Founder, Director -
Steve Krognes,
Chief Financial Officer, Treasurer -
Carole Ho,
Chief Medical Officer, Head of Development -
Alexander Schuth,
Co-Founder, Chief Operating Officer, Secretary -
Dr. Ryan J. Watts Ph.D.,
Co-Founder, Pres, CEO & Director -
Steve Edward Krognes,
CFO & Treasurer -
Dr. Carole Ho,
Chief Medical Officer & Head of Devel. -
Dr. Alexander O. Schuth M.D.,
Co-Founder, COO & Sec. -
Dr. Carole Ho M.D.,
Chief Medical Officer & Head of Devel. -
Vicki Sato,
Independent Chairman of the Board -
Marc Tessier-Lavignec,
Independent Director -
Peter Klein,
Independent Director -
David Schenkein,
Independent Director -
Jay Flatley,
Independent Director -
Douglas Cole,
Independent Director -
Robert Nelsen,
Independent Director -
Jennifer Cook,
Independent Director -
Dr. Marc Tessier-Lavigne Ph.D.,
Co-Founder, Chairman of Scientific Advisory Board & Independent Director -
Dr. Marc Tessier-Lavigne,
Co-Founder, Chairman of Scientific Advisory Board & Independent Director -
Chris Walsh,
Associate Gen. Counsel -
Dr. Laura Hansen,
VP of Investor Relations -
Joe Lewcock,
Chief Scientific Officer -
Dr. Dana Andersen,
Chief Technical and Manufacturing Officer -
Tyler M. Nielsen,
VP of Corp. Fin. -
Douglas Kakdl, L.P.Neuro Li...,
-
Ventures Fund V, L.P.Afeyan...,
-
Marc Tessier Lavigne,
Director -
Ltd Fil,
-
Llc Fmr,
-
Venture Fund Viii, L.P.Arch...,
-
Douglas K Neuro Line Partne...,
-
Douglas Kakdl, L.P.Crestlin...,
-
Nancy Thornberry,
Director -
Erik Harris,
Director